Pharmaceuticals
Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers
SUZHOU, China, and HOUSTON, May 19, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, ...
2020-05-19 07:30
6221
Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
* STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect. * Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remiss...
2020-05-15 12:01
3671
Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
DAEJEON, South Korea, May 15, 2020 /PRNewswire/ -- Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company, presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio's AI drug discovery solution, at the 2020 American Assoc...
2020-05-15 12:01
4259
Duke-NUS, GenScript and A*STAR launch first-in-the-world SARS-CoV-2 serology test to detect neutralising antibodies without need of containment facility or specimen
* As a first-in-the-world "rapid smart test kit", the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficac...
2020-05-15 11:52
7413
Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
SUZHOU, China, May 15, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseas...
2020-05-15 07:30
7797
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo(R) (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
PLYMOUTH MEETING, Pennsylvania, May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company's DNA medicine INO-5401, in combination with INO-9012 an...
2020-05-14 19:00
4227
SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome
CHENGDU, China, May 13, 2020 /PRNewswire/ -- SciMount Pharmatech, Co. Ltd., a wholly-owned subsidiary ofXiling Lab, announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for SMP-100 for the treatment of Irritable Bowel Synd...
2020-05-14 18:00
1214
Halodine(R) Nasal and Oral Antiseptics Show Rapid Antiviral Activity Against SARS-CoV-2 (COVID-19)
FORT LAUDERDALE, Florida, May 14, 2020 /PRNewswire/ -- Veloce BioPharma LLC reports today that their Halodine® Antiseptics have demonstrated rapid viricidal efficacy against SARS-CoV-2, the virus that causes COVID-19. Halodine® is a proprietary povidone-iodine antiseptic developed in partnership ...
2020-05-14 09:26
3341
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma
SUZHOU, China, May 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic and other major diseases, today jointl...
2020-05-14 07:30
9060
Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
- Results from two studies of BAVENCIO® to be featured in ASCO press briefing - Primary efficacy, biomarker and HRQoL analyses for tepotinib†, the first MET inhibitor to have received a regulatory approval for NSCLC withMET gene alterations - Two-year follow-up for first-in-class bifunctional im...
2020-05-14 06:46
2526
Hetero Enters Into a Licensing Agreement With Gilead Sciences, Inc. for the Manufacturing and Distribution of "Remdesivir" in 127 Countries, Including India, for COVID-19
HYDERABAD, India, May 14, 2020 /PRNewswire/ -- Hetero, one of India's leading generic pharmaceutical companies and the world's largest producer of anti-retroviral drugs, announced today that it has entered into a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distributio...
2020-05-14 01:56
3490
First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors
SHANGHAI and ROCKVILLE, Md., May 13, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today announ...
2020-05-13 20:00
5351
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-al...
2020-05-13 18:30
3057
Cipla Enters Into a Licensing Agreement With Gilead to Expand Access to COVID-19 Treatment
MUMBAI, India, May 13, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (and hereafter referred to as "Cipla") today announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine R...
2020-05-13 17:51
3448
ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research
SHANGHAI, May 12, 2020 /PRNewswire/ -- Shanghai ChemPartner announced they have entered into a non-exclusive agreement with the Mount Sinai Health System ( Mount Sinai) to assist in a trial production run of a component of the Mount Sinai COVID-19 serological assay that recently received Emergency...
2020-05-12 23:03
2023
China Biologic Products to Report First Quarter 2020 Financial Results
BEIJING, China, May 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its first quarter 2020 financial res...
2020-05-12 20:30
9732
QPS Announces Novel Coronavirus/COVID-19 Testing Capability
NEWARK, Delaware, May 12, 2020 /PRNewswire/ -- QPS, a global contract research organization (CRO) that provides GLP-compliant discovery, preclinical, and clinical drug development services, announces a newly developed capability to conduct COVID-19 testing, available as ofMonday, May 11, 2020. QP...
2020-05-12 19:11
2807
Merck Granted U.S. Patents for Foundational CRISPR-Cas9 Technology
- Technology provides more tools to fight difficult-to-treat diseases - Life Science business actively licensing its CRISPR-Cas9 technology for therapeutic and other uses - Committed to ethical use of genome-editing technology DARMSTADT, Germany, May 11, 2020 /PRNewswire/ -- Merck, a leading...
2020-05-11 21:00
2813
Technopath Clinical Diagnostics Expands Its Portfolio of Third-party Quality Control Solutions for COVID-19 as Clinical Laboratories Globally Ramp Up Antibody Testing
NEW YORK and BALLINA, Ireland, May 11, 2020 /PRNewswire/ -- Technopath Clinical Diagnostics today launched its Multichem ID-COVID-19 Quality Control Solutions offering laboratories third-party quality control products enabling an independent, totally unbiased assessment of a diagnostic device or ...
2020-05-11 14:00
3216
Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker
SEOUL, South Korea, May 11, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) unveiled for the first time the phase 3 clinical data of Fexuprazan, a novel gastroesophageal reflux disease agent at Digestive Disease Week (DDW) 2020. The abstract of Fexuprazan has been rated in the top 10% pos...
2020-05-11 08:00
5288
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6217
